CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.
作者信息
Moertel Christopher, Martinez-Puerta Francisco, Pluhar Grace G Elizabeth, Castro Maria Graciela, Olin Michael
机构信息
Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Department of Veterinary Clinical Sciences, University of Minnesota Twin Cities, Minneapolis, MN, USA.
出版信息
Expert Opin Investig Drugs. 2022 Sep;31(9):875-879. doi: 10.1080/13543784.2022.2108588. Epub 2022 Aug 3.
Abstract
摘要
相似文献
1
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.CD200AR-L：治疗高级别脑肿瘤的作用机制及临床前和临床见解
Expert Opin Investig Drugs. 2022 Sep;31(9):875-879. doi: 10.1080/13543784.2022.2108588. Epub 2022 Aug 3.
2
CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.CD200 检查点逆转：免疫治疗的新方法。
Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. Epub 2019 Oct 17.
3
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.免疫检查点抑制剂治疗胶质母细胞瘤的成功实施面临的挑战。
Int J Mol Sci. 2020 Apr 16;21(8):2759. doi: 10.3390/ijms21082759.
4
Ipilimumab: an investigational immunotherapy for glioblastoma.伊匹单抗：胶质母细胞瘤的一种实验性免疫疗法。
Expert Opin Investig Drugs. 2020 Nov;29(11):1187-1193. doi: 10.1080/13543784.2020.1826436. Epub 2020 Oct 6.
5
Extrinsic factors associated with the response to immunotherapy in glioblastoma.与胶质母细胞瘤免疫治疗反应相关的外在因素。
Cancer Lett. 2021 Jul 28;511:47-55. doi: 10.1016/j.canlet.2021.04.018. Epub 2021 Apr 29.
6
Glucocorticoids and immune checkpoint inhibitors in glioblastoma.糖皮质激素和免疫检查点抑制剂在胶质母细胞瘤中的应用。
J Neurooncol. 2021 Jan;151(1):13-20. doi: 10.1007/s11060-020-03439-2. Epub 2020 Feb 27.
7
Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.免疫治疗方法在多形性胶质母细胞瘤治疗中的应用：机制与临床应用。
Int J Mol Sci. 2023 Jun 23;24(13):10546. doi: 10.3390/ijms241310546.
8
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.免疫检查点阻断疗法治疗胶质母细胞瘤的研究进展。
Front Immunol. 2020 Nov 30;11:592612. doi: 10.3389/fimmu.2020.592612. eCollection 2020.
9
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.基于主体的建模揭示了肿瘤微环境对联合替莫唑胺/免疫检查点阻断治疗胶质母细胞瘤短期成功的作用。
J Pharmacol Exp Ther. 2023 Oct;387(1):66-77. doi: 10.1124/jpet.122.001571. Epub 2023 Jul 13.
10
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).用抗 CD40 和有丝分裂纺锤体检验点控制器 BAL101553（利斯伐他汀）治疗 ICB 耐药性神经胶质瘤。
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
引用本文的文献
1
Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.靶向乳腺癌中的CD200：免疫治疗策略中的机遇与挑战
Int J Mol Sci. 2024 Dec 26;26(1):115. doi: 10.3390/ijms26010115.
2
Breed-Associated Differences in Differential Gene Expression Following Immunotherapy-Based Treatment of Canine High-Grade Glioma.基于免疫疗法治疗犬高级别胶质瘤后差异基因表达的品种相关差异
Animals (Basel). 2024 Dec 26;15(1):28. doi: 10.3390/ani15010028.
3
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.使用序贯原发性和肿瘤逃逸选择性溶瘤病毒的诱捕和伏击疗法。
Mol Ther Oncolytics. 2023 May 22;29:129-142. doi: 10.1016/j.omto.2023.05.006. eCollection 2023 Jun 15.
4
Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade.消除癌症：CD200/CD200R阻断的免疫治疗潜力。
Front Oncol. 2023 Jan 23;13:1088038. doi: 10.3389/fonc.2023.1088038. eCollection 2023.
本文引用的文献
1
Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma.胃腺癌中免疫检查点的预后价值及免疫功能综合分析
Int J Gen Med. 2021 Sep 17;14:5807-5824. doi: 10.2147/IJGM.S325467. eCollection 2021.
2
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.CD200 免疫检查点肽通过 DAP10 信号通路引发抗神经胶质瘤反应。
Neurotherapeutics. 2021 Jul;18(3):1980-1994. doi: 10.1007/s13311-021-01038-1. Epub 2021 Apr 7.
3
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.免疫检查点抑制剂在癌症治疗中的应用：临床影响及反应和耐药的机制。
Annu Rev Pathol. 2021 Jan 24;16:223-249. doi: 10.1146/annurev-pathol-042020-042741. Epub 2020 Nov 16.
4
CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.CD200 检查点逆转：免疫治疗的新方法。
Clin Cancer Res. 2020 Jan 1;26(1):232-241. doi: 10.1158/1078-0432.CCR-19-2234. Epub 2019 Oct 17.
5
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.在慢性淋巴细胞白血病和多发性骨髓瘤中的 samalizumab 的 I 期研究：阻断免疫检查点 CD200。
J Immunother Cancer. 2019 Aug 23;7(1):227. doi: 10.1186/s40425-019-0710-1.
6
Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma.高级别胶质瘤宠物犬术后联合CD200免疫检查点抑制剂与肿瘤裂解物疫苗接种的治疗
Cancers (Basel). 2019 Jan 24;11(2):137. doi: 10.3390/cancers11020137.
7
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).免疫疗法的展望：免疫疗法桥接会议报告（2017 年 11 月 29-30 日，意大利那不勒斯）。
J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z.
8
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.含有CD200的肿瘤衍生疫苗会抑制免疫激活：对免疫治疗的启示。
Immunotherapy. 2016 Sep;8(9):1059-71. doi: 10.2217/imt-2016-0033.
9
The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.免疫抑制配体PD-L1和CD200与急性髓系白血病T细胞免疫抑制相关联：一种新的免疫治疗突触的鉴定。
Leukemia. 2015 Sep;29(9):1952-4. doi: 10.1038/leu.2015.62. Epub 2015 Mar 9.
10
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.CD200 在中枢神经系统肿瘤诱导的免疫抑制中的作用：CD200 通路阻断在靶向免疫治疗中的作用。
J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.
Zotero 插件